Robert L. Fine, MD presented encouraging results from a phase II clinical trial using a combination of chemotherapy (CAPTEM) in patients with various types of neuroendocrine tumors at the ASCO GI conference in San Francisco, CA yesterday. 28 patients with carcinoid (various primary locations), pancreatic neuroendocrine tumors and other types of neuroendocrine tumors were enrolled in this study and for these patients, the median progression-free survival reached almost two years. In particular, Dr. Fine reported that 11% of patients achieved complete responses, 32% had partial responses, and 54% had stable disease during treatment. While this trial is still ongoing, and the sample size was small, the data suggest that this may be a promising treatment strategy for neuroendocrine tumor patients in the future. To learn more read Dr. Fine’s abstract or this press release.
The data from this study are encouraging and this therapy will be further studied in a large, randomized phase II clinical trial for patients with pancreatic neuroendocrine tumors.
Any patient considering this, or any other treatment should always consult with a physician well-versed in treating neuroendocrine cancers.